November 7, 2019, Toronto, Ontario, Canada. Circa Life Sciences Inc.  is pleased to announce the appointment of Leo Dominguez as Chief Strategy officer.

Leo built a direct sales organization at Immunotec Research Ltd. which handled millions a year in nutraceutical sales.  Following his passion for technology, he founded BitSent Inc. and BTC Mining Inc.  As an early pioneer in cryptocurrencies he built BitSent into the largest national cryptocurrency ATM company in Canada, and built two separate MegaWatt-class cryptomining data centers for BTC Mining.

Leo studied Science at the University of Waterloo, earning a B.Sc., Honors Science with a Biology Minor and Scientific Computing Option.

Prior to Circa, Leo was Chief Strategic Officer of Qualis Cannabis Corp., Leo oversaw and developed many initiatives including: genetics transfers and acquisition, breeding and propagation, adult beverage, pet products, scientific and educational marketing, international CBD/hemp development projects, and domestic cultivation.

“I am delighted to join the team at Circa, I believe the vision they have created for the company is exactly what is required to make it a global leader in the CBD industry. I look forward to being a part of the success of Circa.”

– Leo Dominguez.

Leo joins a diverse team of specialists at Circa, where he will be supported by industry leading scientists, technologists, commodity traders, and sales teams.

“The entire team at Circa is excited to have someone of Leo Dominguez’s stature join Circa. He could have selected any of the biggest companies in the cannabis/cbd industry to join, and we are honored to have been selected. Leo’s experience in Genetics as well as block-chain technology will help guide Circa’s fully integrated business plan which will be monitored from “seed to consumer”.  

-Jazz Samra, founder and president of Circa Life Sciences Inc. 

About Circa Life Sciences

Circa Life Science Inc is a Canadian based vertically integrated company focused on the CBD industry, including cultivation, processing, manufacturing, extraction and research and development. Circa will be developing and commercializing top quality medically – validated products, and promoting breakthrough research for the newly created CBD Industry in many countries around the world. Our vision is to become a global leader in providing safe and effective cannabinoid products. From product and process innovation to market execution and everything in between, we are driven by a passion for leadership, and a commitment to drive the industry forward.

Forward-Looking Information

Certain statements contained in this new release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Circa’s current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and Circa Life Sciences is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein. We seek safe harbor.

November 7, 2019, Toronto, Ontario, Canada. Circa Life Sciences Inc.  is pleased to announce the appointment of Dr Divy Patel as Chief Medical officer.

Dr Patel has a diverse career working in Pediatrics & Infectious Diseases and Internal medicine. He is both UK and Canada registered as a Physician. He has previously worked in diverse areas of medicine including South Africa, England and Australia. He has served as an independent advisor to Pfizer and Valneuva. He regularly attends advisory board meetings for new product developments in travel medicine. He has a keen interest in telemedicine, EMR access for patient records and is currently working on virtual care clinics.

Dr Patel will be leading and managing Circa’s Science Team is to promote the rapid expansion of CBD based products in the health field. The team will be developing a platform to reduce addictive urges such as; opiate abuse and dependence.

“My objective with Circa Life Sciences is to promote the rapid expansion of CBD based products in the health field” says Dr Patel. “I see Circa as the perfect incubator all CBD related compounds, cosmeceuticals and applications for novel therapies. I welcome the opportunity to solidify my role as medical director for Circa Life Sciences. It is a great environment to work in, and having a team of directors which bring such diversity, and fosters a cohesive environment in which to grow. “

“With our Company’s focus on commercializing and expanding its science and technology, Dr Patel fills a critical role in furthering our corporate and scientific objectives and we are extremely pleased to have someone of his caliber join our team.” says Jazz Samra – founder and president of Circa Life Sciences Inc.  “Dr Patel has a proven track record of clinical development and he will play an instrumental role in Circa”.

About Circa Life Sciences

Circa Life Science Inc is a Canadian based company focused on cover all aspects of the cbd industry, including cultivation, processing, manufacturing, extraction and research and development. Circa will be developing and commercializing top quality medically – validated products, oils and promoting breakthrough research for the newly created CBD Industry in many countries around the world. Our vision is to become a global leader in providing safe and effective cannabinoid products. From product and process innovation to market execution and everything in between, we are driven by a passion for leadership, a commitment to drive the industry forward.

Forward-Looking Information

Certain statements contained in this new release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Circa’s current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and Circa Life Sciences is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein. We seek safe harbor.